THC and Migraine Relief: What a Clinical Trial Found

In a randomized clinical trial of adults with migraine, about 69% of attacks treated with THC-dominant cannabis had pain relief after two hours, compared with 47% of attacks treated with placebo. Researchers tested THC-dominant cannabis separately from CBD-dominant cannabis and a THC–CBD combination.

What the trial tested

The trial, published in Headache, enrolled 92 adults who treated 247 migraine attacks. Participants used vaporized study flower in four formulations across separate attacks: THC-dominant (6% THC), CBD-dominant (11% CBD), a combination (6% THC and 11% CBD), and placebo. The order was randomized.

Pain relief and being pain-free

With THC-dominant cannabis, more attacks improved at two hours than with placebo. The difference in how often pain went away completely did not reach statistical significance. The THC–CBD combination improved both measures. Results for CBD-dominant cannabis were similar to placebo on the two-hour measures.

What the study leaves open

The trial looked at treatment during a migraine attack. It leaves open whether the same formulations can prevent migraine and what the effects of frequent, long-term use might be. The findings apply to the specific vaporized preparations studied.

Read the clinical trial in Headache.

Leave a Comment